CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
This walkthrough guides you through stock index calculation with a concrete example, detailing data inputs, weighting decisions, and the final result.
17,212 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Insider sales in biotech can spark questions about a company’s future. This guide breaks down what to watch, how to r...
Marvell Technology has staged a decisive run in 2026, outpacing Broadcom in the AI accelerator stock race. As data-ce...
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Ark Invest's July activity shows notable interest in Kratos Defense. This article breaks down what the buys mean, the...
A top Sea Limited executive sold a sizable stake, triggering questions about the stock's future. This guide breaks do...
A prominent hedge fund reduced its Wix stake by 25,000 shares in late 2025. This article breaks down what dorsal capi...
A Murphy USA senior executive recently sold shares in an open-market move valued at roughly $344,000. This article br...
Nu Holdings faced a sharp February drop as U.S. expansion uncertainty and broader macro headwinds collided with stron...
Boone Capital just disclosed a fresh position in HealthEquity, raising questions about the stock's potential. This gu...
A big stake in Sotera Health has caught the market's eye as shares slide. This article breaks down what a $175 millio...
Apple sits around $284 as traders weigh the next move. A robust quarter and expanding Services set the stage for a bu...